SCHEMBL12115136

SCHEMBL12115136

[CH2-][CH+]c1ccc(Cl)cc1CNCCOC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.64
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ PKM P14618 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CYP1A2 P05177 3/20 0.39
▸ CYP2D6 P10635 3/20 0.39
▸ ADRA1D P25100 2/20 0.38
▸ ADRA1A P35348 2/20 0.38
▸ ADRA1B P35368 2/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8147674 0.79 HTT (0.72) HTTMAPTTHRBALDH1A1KDM4E
SCHEMBL12115144 0.78 SLC6A4 (0.49) —
SCHEMBL12113626 0.76 HTT (0.44) HTTMAPTALDH1A1KDM4EPKM
SCHEMBL20582079 0.72 HTT (0.58) HTTMAPTTHRBALDH1A1KDM4E
SCHEMBL20582107 0.71 HTT (0.57) HTTMAPTTHRBALDH1A1KDM4E
SCHEMBL11304095 0.71 L3MBTL1 (0.67) HTTTHRBALDH1A1KDM4EPKM
SCHEMBL12113623 0.71 HTT (0.43) HTTMAPTKDM4ECYP1A2LMNA
SCHEMBL5768941 0.69 HTT (0.63) HTTMAPTALDH1A1L3MBTL1CYP2D6
Hydrochloric Acid SCHEMBL16097364 0.69 L3MBTL1 (0.70) HTTTHRBALDH1A1KDM4EPKM
SCHEMBL12113551 0.69 HTR2C (0.44) HTTMAPTKDM4EL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 — — US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 HTT 330/4885MAPT 1553/4885THRB 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback